Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China More Information Corresponding author: [email protected] Received Date: January 22, 2024 Accepted Date: September 02, 2024 Published Online: September 03, 2024 REFERENCES ABOUT THIS ARTICLE Cite this article: Xu Y
Phase II data showed that a 24mg dose of CT-388 enabled 54 percent of participants to attain resolution of obesity
Treatment time is a vanity metric
Mechanistically, activation of GLP-1R by GLP-1 or exenatide phosphorylates STAT3, which drives human monocyte-derived macrophages to develop an M2 phenotype marked by increased expression of CD163, CD204, and IL-10 [86]
These symptoms differ from common Rybelsus side effects and require prompt medical assessment